<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>分子设计 | wechat-feeds</title><link>http://MzI4NDg5MzIwMQ.favicon.privacyhide.com/favicon.ico</link><description>药物分子设计是药物发现中思维的挥洒，让我们一起来品鉴药物分子设计师们的作品，成药上市须有时，原创设计贺精彩。</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 14 Jun 2021 10:05:58 +0800</pubDate><image><url>http://MzI4NDg5MzIwMQ.favicon.privacyhide.com/favicon.ico</url><title>分子设计 | wechat-feeds</title><link>http://MzI4NDg5MzIwMQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>【First-in-class药设系列】变构设计在蛋白工程中的应用与展望</title><link>https://mp.weixin.qq.com/s/AMBlg_3VkhCJw78X008ipw</link><description></description><content:encoded><![CDATA[【First-in-class药设系列】变构设计在蛋白工程中的应用与展望]]></content:encoded><pubDate>Mon, 14 Jun 2021 07:33:34 +0800</pubDate></item><item><title>【First-in-class药设系列】靶向p53突变的双特异性抗体设计</title><link>https://mp.weixin.qq.com/s/u6soH1jWU-Nu1A-b2B5C-g</link><description></description><content:encoded><![CDATA[【First-in-class药设系列】靶向p53突变的双特异性抗体设计]]></content:encoded><pubDate>Sun, 06 Jun 2021 14:15:10 +0800</pubDate></item><item><title>【First-in-class药设系列】靶向蛋白复合体的药物研发机遇与挑战</title><link>https://mp.weixin.qq.com/s/iA7nhXztdbV-dW0aAARYaQ</link><description></description><content:encoded><![CDATA[【First-in-class药设系列】靶向蛋白复合体的药物研发机遇与挑战]]></content:encoded><pubDate>Sun, 30 May 2021 21:38:10 +0800</pubDate></item><item><title>【First-in-class药设系列】靶向钙敏感受体的变构药物研发进展</title><link>https://mp.weixin.qq.com/s/u2OvAg_J9r6MNhaYXJx76w</link><description></description><content:encoded><![CDATA[【First-in-class药设系列】靶向钙敏感受体的变构药物研发进展]]></content:encoded><pubDate>Sun, 23 May 2021 22:22:49 +0800</pubDate></item><item><title>【First-in-class药设系列】2020年全球上市新药的靶标浅析</title><link>https://mp.weixin.qq.com/s/RkmVecwegNM8HEKE24MEcQ</link><description></description><content:encoded><![CDATA[【First-in-class药设系列】2020年全球上市新药的靶标浅析]]></content:encoded><pubDate>Sun, 16 May 2021 22:29:18 +0800</pubDate></item><item><title>张健团队指导本科生蝉联上海市“挑战杯”特等奖</title><link>https://mp.weixin.qq.com/s/hVf0KV2yze-D4VK-JjdiKw</link><description></description><content:encoded><![CDATA[张健团队指导本科生蝉联上海市“挑战杯”特等奖]]></content:encoded><pubDate>Wed, 12 May 2021 08:43:02 +0800</pubDate></item><item><title>【First-in-class药设系列】ABHD17首个高选择性抑制剂的设计与发现</title><link>https://mp.weixin.qq.com/s/zhDSKgz-80JCg5mTdzDj-A</link><description></description><content:encoded><![CDATA[【First-in-class药设系列】ABHD17首个高选择性抑制剂的设计与发现]]></content:encoded><pubDate>Mon, 10 May 2021 13:08:00 +0800</pubDate></item><item><title>【First-in-class药设系列】MTAP缺失肿瘤的新型MAT2A抑制剂设计</title><link>https://mp.weixin.qq.com/s/zQSOnt_OD55c5ruXHXLRWg</link><description></description><content:encoded><![CDATA[【First-in-class药设系列】MTAP缺失肿瘤的新型MAT2A抑制剂设计]]></content:encoded><pubDate>Sun, 02 May 2021 20:54:58 +0800</pubDate></item><item><title>【First-in-class药设系列】针对晚期实体瘤的AKT变构抑制剂TAS-117临床研究进展</title><link>https://mp.weixin.qq.com/s/5s1iCzYdctJn5wVQ7N9aTQ</link><description></description><content:encoded><![CDATA[【First-in-class药设系列】针对晚期实体瘤的AKT变构抑制剂TAS-117临床研究进展]]></content:encoded><pubDate>Sun, 25 Apr 2021 22:14:21 +0800</pubDate></item><item><title>【First-in-class药设系列】EGFR变构抑制剂在非小细胞肺癌治疗中的进展</title><link>https://mp.weixin.qq.com/s/UWj5ezFEeHZtFzGbCnyz3A</link><description></description><content:encoded><![CDATA[【First-in-class药设系列】EGFR变构抑制剂在非小细胞肺癌治疗中的进展]]></content:encoded><pubDate>Mon, 19 Apr 2021 22:34:27 +0800</pubDate></item></channel></rss>